Can Creatine Really Help Treat Depression?

Why it sounds plausible

Creatine and phosphocreatine help buffer energy availability in cells, including the brain. Researchers have therefore explored whether supplementation might influence symptoms in conditions involving altered brain energy processes. That is a reason for trials, not proof that depression is a creatine deficiency or that more brain energy automatically means recovery. [1]

What the broader meta-analysis found

A systematic review published in late 2025 pooled 11 trials with 1,093 participants, including people with and without depression. The average standardised effect favoured creatine, but certainty was rated very low and results varied substantially. The estimated change corresponded to about 2.2 points on a common depression scale, below the review's three-point threshold for an important difference. [1]

The confidence interval allowed effects that would not be clinically important, and analyses raised concern about bias favouring creatine. Some secondary outcomes looked more positive than others. Taken together, the review leaves a worthwhile research signal while allowing that the true average benefit could be trivial or absent. [1]

The 2026 review asks a narrower clinical question

A later systematic review of diagnosed mental disorders included five randomised trials, with 238 participants. Four concerned major depression and one bipolar depression. Creatine was studied over four to eight weeks as an addition to medication or psychotherapy. Findings were mixed: some combinations were promising, while other comparisons did not clearly outperform placebo. [2]

This does not contradict the larger trial count above. The reviews used different eligibility criteria and populations. A review that includes depressive-symptom measures in people without a diagnosed disorder answers a broader question than one restricted to clinical mental disorders. [1][2]

What about creatine alongside CBT?

An eight-week pilot trial compared creatine plus cognitive behavioural therapy with placebo plus the same therapy. The published report found a favourable symptom signal, making the combination worth studying further. It was explicitly a pilot feasibility and exploratory study. It did not show that creatine can replace CBT, or establish an effect for every person with depression. [3]

An additional-treatment trial also cannot simply be relabelled a test of creatine alone. The relevant comparison is the benefit added to the treatment both groups received, rather than improvement from baseline in the creatine group.

The catch: uncertainty includes safety and suitability

Small samples, brief follow-up, different diagnoses and treatment combinations make a single dependable benefit estimate difficult. Depression ratings, remission and durable everyday recovery are different outcomes. Evidence from physical-performance studies cannot fill these clinical gaps. [1][2]

The 2026 review reported hypomania or mania in two of 17 creatine participants in the bipolar-depression trial. That small observation cannot establish an exact risk, but it is an important reason for particular caution in bipolar disorder or a history of mood elevation. General supplement familiarity does not establish suitability for every psychiatric condition. [2]

What this means for you

If you are interested in creatine for depression, discuss it with the clinician overseeing your care, particularly if you have bipolar disorder, past mania or other medical considerations. Do not stop or reduce prescribed treatment to try it. The evidence concerns supervised research combinations rather than a proven self-treatment plan. [2][3]

Keep the distinction between a plausible option for future research and a dependable treatment recommendation. Talking therapies and other established approaches remain part of guideline-based care; supplement research should add to that discussion rather than displace it. [4]

Research & Sources

Check the evidence yourself. Access limitations and indirect evidence are identified below.

Evidence reviewed: October 2026

Targeted editorial review of sources available on 24 October 2026, not an exhaustive systematic review. Evidence vs Hype provides education, not individual medical diagnosis or treatment. Original AI-generated artwork is illustrative and does not show a study result. No commercial product was selected or endorsed.